NasdaqGM:XLRN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Acceleron Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XLRN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.3%

XLRN

-1.2%

US Biotechs

0.4%

US Market


1 Year Return

148.4%

XLRN

32.5%

US Biotechs

17.8%

US Market

Return vs Industry: XLRN exceeded the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: XLRN exceeded the US Market which returned 17.8% over the past year.


Shareholder returns

XLRNIndustryMarket
7 Day-3.3%-1.2%0.4%
30 Day0.3%2.3%6.1%
90 Day7.8%-2.6%8.9%
1 Year148.4%148.4%34.7%32.5%20.5%17.8%
3 Year178.0%178.0%20.0%14.0%42.3%32.9%
5 Year227.8%227.8%11.5%3.4%84.2%63.4%

Price Volatility Vs. Market

How volatile is Acceleron Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Acceleron Pharma undervalued compared to its fair value and its price relative to the market?

40.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XLRN ($109.34) is trading below our estimate of fair value ($181.52)

Significantly Below Fair Value: XLRN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XLRN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: XLRN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XLRN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XLRN is overvalued based on its PB Ratio (14x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Acceleron Pharma forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

60.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XLRN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XLRN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XLRN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XLRN's revenue (41.3% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: XLRN's revenue (41.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: XLRN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Acceleron Pharma performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XLRN is currently unprofitable.

Growing Profit Margin: XLRN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XLRN is unprofitable, and losses have increased over the past 5 years at a rate of 20.7% per year.

Accelerating Growth: Unable to compare XLRN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XLRN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: XLRN has a negative Return on Equity (-32.81%), as it is currently unprofitable.


Next Steps

Financial Health

How is Acceleron Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: XLRN's short term assets ($449.0M) exceed its short term liabilities ($37.4M).

Long Term Liabilities: XLRN's short term assets ($449.0M) exceed its long term liabilities ($20.5M).


Debt to Equity History and Analysis

Debt Level: XLRN is debt free.

Reducing Debt: XLRN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XLRN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XLRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Acceleron Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XLRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XLRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XLRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XLRN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XLRN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Habib Dable (51 yo)

3.83yrs

Tenure

US$4,273,088

Compensation

Mr. Habib J. Dable has been the Chief Executive Officer and President at Acceleron Pharma Inc. since joining in December 1, 2016. Mr. Dable served as the President of Bayer HealthCare Pharmaceuticals Inc., ...


CEO Compensation Analysis

Compensation vs Market: Habib's total compensation ($USD4.27M) is below average for companies of similar size in the US market ($USD7.31M).

Compensation vs Earnings: Habib's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Habib Dable
CEO, President & Director3.83yrsUS$4.27m0.073%
$ 4.7m
Thomas Maniatis
Co-Founder17.75yrsUS$245.02kno data
Kevin McLaughlin
Senior VP9.92yrsUS$1.46m0.019%
$ 1.2m
Ravindra Kumar
Chief Scientific Officer & Senior VPno dataUS$1.21m0.13%
$ 8.4m
Sujay Kango
Executive VP & Chief Commercial Officer2.67yrsUS$1.37m0.0071%
$ 463.6k
Mark Ptashne
Co-Founder and Member of Scientific Advisory Boardno datano datano data
Lisa Wyman
Senior Vice President of Technical Operations0.75yrno datano data
Todd James
Senior VP of Corporate Affairs & Investor Relationsno datano datano data
Adam Veness
Senior VPno datano data0.032%
$ 2.1m
Matthew Fearer
Director of Corporate Communicationsno datano datano data
Kevin McManus
Chief Human Resources Officer1.75yrsno datano data
James Desiderio
Senior Vice President of Regulatory & Quality2.75yrsno datano data

3.3yrs

Average Tenure

56yo

Average Age

Experienced Management: XLRN's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Habib Dable
CEO, President & Director3.83yrsUS$4.27m0.073%
$ 4.7m
Thomas Maniatis
Co-Founder17.75yrsUS$245.02kno data
Mark Ptashne
Co-Founder and Member of Scientific Advisory Boardno datano datano data
Terrence Kearney
Independent Director6.25yrsUS$287.52k0.0086%
$ 555.8k
Christopher Hite
Director0.33yrno datano data
Bruce Spiegelman
Member of Scientific Advisory Boardno datano datano data
Joseph Zakrzewski
Independent Director9.58yrsUS$291.27k0.055%
$ 3.6m
Joan Massague
Member of Scientific Advisory Boardno datano datano data
Francois Nader
Independent Chairman of the Board5.58yrsUS$303.77k0.0086%
$ 555.8k
Kemal Malik
Independent Director0.75yrno data0%
$ 0
Thomas McCourt
Independent Director4.25yrsUS$281.27k0.0074%
$ 479.2k
Karen Smith
Independent Director2.92yrsUS$271.27k0.0049%
$ 318.8k

4.3yrs

Average Tenure

60.5yo

Average Age

Experienced Board: XLRN's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.4%.


Top Shareholders

Company Information

Acceleron Pharma Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Acceleron Pharma Inc.
  • Ticker: XLRN
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.493b
  • Shares outstanding: 59.90m
  • Website: https://www.acceleronpharma.com

Number of Employees


Location

  • Acceleron Pharma Inc.
  • 128 Sidney Street
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XLRNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 2013
0A3DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013

Biography

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the trea ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 00:31
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.